

[54] ML-236B DERIVATIVES AND THEIR PREPARATION

[75] Inventors: Akira Terahara; Minoru Tanaka, both of Hiromachi, Japan

[73] Assignee: Sankyo Company, Limited, Tokyo, Japan

[21] Appl. No.: 270,846

[22] Filed: Jun. 5, 1981

[30] Foreign Application Priority Data

Jun. 6, 1980 [JP]	Japan	55-76127
Aug. 22, 1980 [JP]	Japan	55-115483
Sep. 8, 1980 [JP]	Japan	55-124385
Sep. 19, 1980 [JP]	Japan	55-130311

[51] Int. Cl.³ C07C 69/013

[52] U.S. Cl. 560/119; 560/256; 424/305; 435/135; 549/292

[58] Field of Search 560/119, 256

[56] References Cited

U.S. PATENT DOCUMENTS


4,137,322	1/1979	Endo et al.	424/273
-----------	--------	-------------	---------

Primary Examiner—Robert Gerstl

Attorney, Agent, or Firm—Frishauf, Holtz, Goodman & Woodward


[57] ABSTRACT

Compounds of formula (I):




(I)

(wherein R represents a group of formula



or



and the corresponding ring-closed lactones, salts (especially alkali metal salts) and esters (especially C₁-C₅ alkyl esters) thereof may be prepared by subjecting ML-236B, or ML-236B carboxylic acid or a salt or ester thereof to enzymatic hydroxylation, which may be effected by means of microorganisms of the genera *Mucor*, *Rhizopus*, *Zygorynchus*, *Circinella*, *Actinomucor*, *Gongronella*, *Phycomyces*, *Martierella*, *Pycnoporus*, *Rhizoctonia*, *Absidia*, *Cunninghamella*, *Syncephalastrum* and *Streptomyces*, or cell-free, enzyme-containing extracts from said microorganisms. The compounds are capable of inhibiting biosynthesis of cholesterol and are thus useful in the treatment of hypercholesteraemia.

25 Claims, 5 Drawing Figures

Fig 1




Fig 2




Fig 3




Fig 4





Fig 5




ML-236B DERIVATIVES AND THEIR PREPARATION

BACKGROUND OF THE INVENTION

The present invention relates to a series of new derivatives of the known compound ML-236B, to processes for their preparation and to pharmaceutical compositions containing them.

ML-236B, which has the following chemical structure:




is disclosed in U.S. Pat. No. 3,983,140. It has been isolated and purified from the metabolic products of microorganisms of the genus *Penicillium*, especially *Penicillium citrinum*, a species of blue mould. It has been shown to inhibit the biosynthesis of cholesterol by enzymes or cultured cells separated from experimental animals by competing with the rate-limiting enzyme active in the biosynthesis of cholesterol, namely 3-hydroxy-3-methylglutaryl-coenzyme A reductase and, as a result, significantly reduces serum cholesterol levels of animals [Journal of Antibiotics, 29, 1346 (1976)]. A number of compounds structurally related to ML-236B have also been discovered and found to possess the ability to inhibit the biosynthesis of cholesterol.



We have now discovered a series of new compounds, which may be prepared by the enzymatic hydroxylation of ML-236B or of derivatives thereof, and which possess an ability to inhibit the biosynthesis of cholesterol which is at least comparable with, and in some instances substantially exceeds, that of ML-236B itself.

BRIEF SUMMARY OF INVENTION

The compounds of the present invention are those hydroxycarboxylic acids of formula (I):




(in which R represents a group of formula



and ring-closed lactones, salts and esters thereof.


The invention also provides a process for preparing a compound of formula (I), or a ring-closed lactone, salt or ester thereof by the enzymatic hydroxylation of ML-236B, or ML-236B carboxylic acid, or a salt or ester thereof.

ML-236B carboxylic acid has the formula



DETAILED DESCRIPTION OF INVENTION

One class of compounds of the present invention are those compounds of formula (II):



(in which R¹ represents a hydrogen atom or a C₁-C₃ alkyl group), pharmaceutically acceptable salts of the acid wherein R¹ represents a hydrogen atom, and the corresponding lactone of formula (III):

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.